Drug Trial Radar · NCT07064564
iSTEP-N 101b: Pharmacokinetics and Safety Study of iSTEP-N Implant vs Monthly Vivitrol in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
21
Actual
Start
Jul 25, 2026
Primary completion
Oct 1, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Akyso Therapeutics, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute on Drug Abuse (NIDA); Cenexel JBR; Fast-Track Drugs & Biologics, LLC; Aliri Bioanalysis; Ardena; Element Analytics
- First posted
- Jul 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1b clinical study evaluates iSTEP-N, an investigational extended-release subcutaneous implant containing 9.6 g of naltrexone designed to provide continuous drug release over many months. The primary objective is to evaluate naltrexone plasma concentrations and pharmacokinetic (PK) parameters over 12 months following a single iSTEP-N implant placement compared with monthly intramuscular injections of Vivitrol® (380 mg) in healthy adult volunteers. Participants are randomized in a 4:3 ratio to receive either a single 9.6 g iSTEP-N implant (n=12) or monthly Vivitrol injections through Week 49 (n=9). Participants are followed for 12 months in Part 1 to monitor safety, side effects, and plasma drug levels. Participants receiving iSTEP-N who have detectable implant material or measurable naltrexone levels at Week 53 may enter Part 2 for long-term safety and PK follow-up lasting up to two additional years.
Conditions
- Opioid Use Disorder
Interventions
Naltrexone implant, 9.6 gramsDrug
Subcutaneous bioresorbable implant containing 9.6 grams of naltrexone, inserted into the thigh on Day 1 and designed to release drug steadily over 12 months.
Extended-release naltrexone injection, 380 mgDrug
Intramuscular injection of 380 mg extended-release naltrexone (Vivitrol), administered every 4 weeks for 12 months as the active comparator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Naltrexone Plasma Concentration Every 28 Days (C-every-28-days)Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 53
- Percentage of Participants Maintaining Opioid Blockade Naltrexone LevelsTime frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 53
Locations
1 site in 1 country. Site status is shown where the registry gives one.
JBR Cenexel
Millcreek, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.